Angiogenetic potential of Ad2/Hif-1α/VP16 after regional application in a preclinical pig model of chronic ischemia.

abstract：:Statins are beneficial both in the primary and secondary prevention of atherosclerotic vascular disease and acute events in a broad spectrum of patient subgroups. However, the observed clinical benefit with statin therapy is much greater than expected through the reduction of cholesterol levels alone. Clinical and exp...

journal_title：Current vascular pharmacology

authors： Yildirir A,Müderrisoglu H

更新日期：2004-10-01 00:00:00

abstract：:Matrix metalloproteinases (MMP) comprise a family of at least 25 zinc-dependent endopeptidases that play a pivotal role in the physiopathology of the mammalian central nervous system. In the first phases after stroke, the dysregulation of MMPs has been described to increase acute neurovascular disruption and cerebral ...

journal_title：Current vascular pharmacology

authors： Lenglet S,Montecucco F,Mach F

更新日期：2015-01-01 00:00:00

abstract：:Inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis (UC) are idiopathic, intestinal and systemic inflammatory disorders which are immunologically mediated with the activation of plasma proteolytic cascades. The activation of coagulation in IBD is related to the activity and colonic extension of t...

journal_title：Current vascular pharmacology

authors： Stadnicki A

更新日期：2012-09-01 00:00:00

abstract：:Prostaglandins (PGs) belong to the family of prostanoids together with thromboxanes and are produced mainly from arachadonic acid by the enzyme cyclooxygenase. PGs are known to stimulate platelet aggregation, mediate inflammation and edema, play a role in bone metabolism and in biological adaptation of connective tiss...

journal_title：Current vascular pharmacology

authors： Boushel R,Langberg H,Risum N,Kjaer M

更新日期：2004-04-01 00:00:00

abstract：BACKGROUND:Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used, having numerous indications. However, despite their therapeutic role, they are associated with serious cardiovascular (CV) adverse events. Objectives-Methods: This review comprising recent observational studies and metaanalyses over the past few...

journal_title：Current vascular pharmacology

authors： Kontogiorgis C,Valikeserlis I,Hadjipavlou-Litina D,Nena E,Constantinidis TC

更新日期：2016-01-01 00:00:00

abstract：:Fifteen years after its discovery, NO has fully reached an established position in physiology, medicine and therapeutics. It is difficult to find a biological function or a pathological condition where NO does not play a relevant role. Discoveries in the NO field have historically evolved from cardiovascular research,...

journal_title：Current vascular pharmacology

authors： Llorens S,Nava E

更新日期：2003-10-01 00:00:00

abstract：:Post-transplant diabetes mellitus (PTDM) and dyslipidaemia are the most common metabolic complications in kidney transplant recipients (KTR). They are associated with a higher risk of lower graft function and survival, as well as an increased risk of cardiovascular disease (CVD). The aim of this review is to provide c...

journal_title：Current vascular pharmacology

authors： Anagnostis P,Paschou SA,Spartalis E,Sarno G,De Rosa P,Muscogiuri G

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:Vitamin D is a fat soluble vitamin involved in calcium and bone metabolism; recently its deficiency has been related to cardiovascular disease. In cardiac tissue, vitamin D suppresses metalloproteinases (MMPs) expression, enzymes directly associated with vulnerable plaque. OBJECTIVE:To investigate whether t...

journal_title：Current vascular pharmacology

authors： Machulsky NF,Barchuk M,Gagliardi J,Gonzalez D,Lombardo M,Escudero AG,Gigena G,Blanco F,Schreier L,Fabre B,Berg G

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:In various cardiac diseases, thrombembolism constitutes a major risk, and in these patients clinically silent microembolic signals (MES) are detectable within the transcranial Doppler frequency spectrum (TCD) of the major brain arteries. MES are already an accepted surrogate parameter of the future risk of s...

journal_title：Current vascular pharmacology

authors： Dittrich R,Ringelstein EB

更新日期：2008-10-01 00:00:00

abstract：:In patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD), 25OH-vitamin D (calcidiol) deficiency or insufficiency is a common finding with high prevalence. Numerous epidemiological studies have found an independent association of low levels of calcidiol with increased morbidity and mortality. Wi...

journal_title：Current vascular pharmacology

authors： Brandenburg VM,Kruger T

更新日期：2014-03-01 00:00:00

abstract：:The recently published Assessment of Survival and Cardiovascular Events (AURORA) trial showed that rosuvastatin (10 mg/d) compared with placebo did not result in a significant reduction in vascular events despite a 43% fall in low density lipoprotein cholesterol (LDL-C) levels in patients with end-stage renal disease ...

journal_title：Current vascular pharmacology

authors： Athyros VG,Tziomalos K,Karagiannis A,Mikhailidis DP

更新日期：2009-07-01 00:00:00

abstract：:Cardiovascular failure in sepsis involves a combination of hypovolemia, decreased vascular tone, myocardial depression and microcirculatory alterations. Fluids represent the first line therapeutic intervention, with controversy regarding the type of fluid. Recent data indicate that albumin is safe and might even be be...

journal_title：Current vascular pharmacology

authors： De Backer D,Scolletta S

更新日期：2013-03-01 00:00:00

abstract：:The renin-angiotensin system (RAS) plays an essential role in fluid and electrolyte homeostasis and the regulation of vascular tone; however, dysregulation and over-activation of the RAS lead to the pathogenesis of various cardiovascular diseases. The RAS is closely associated with NADPH oxidase, a major enzymatic sou...

journal_title：Current vascular pharmacology

authors： Honjo T,Yamaoka-Tojo M,Inoue N

更新日期：2011-03-01 00:00:00

abstract：:Initially, the progression of chronic venous insufficiency is related to venous hypertension. The earliest complaints or symptoms, as well as vessel wall deterioration, valve restructuring, and, eventually, varicose veins, result not only from elevation of pressure, but also from a cascade of biochemical events relate...

journal_title：Current vascular pharmacology

authors： Katsenis K

更新日期：2005-01-01 00:00:00

abstract：:Both endothelin(ET)-1 and oxidative stress have been the subjects of intense investigation within the cardiovascular field over the past decade and a half, yet little is known about the precise relationship between these important modulators of vascular function. There is a firm evidence that ET-1 can stimulate the pr...

journal_title：Current vascular pharmacology

authors： Pollock DM,Pollock JS

更新日期：2005-10-01 00:00:00

abstract：:Adipocytes are no longer considered just as cells related to storage of energy and thermoregulation. Now we know that they release a huge number of paracrine and endocrine biologically active molecules. This is also the case for perivascular adipose tissue (PVAT) that surrounds almost all blood vessels in the organism...

journal_title：Current vascular pharmacology

authors： Van de Voorde J,Boydens C,Pauwels B,Decaluwé K

更新日期：2014-05-01 00:00:00

abstract：:Immunosuppressive drugs (ISDs) have a major impact on the development and progression of cardiac allograft vasculopathy (CAV), the main cause of cardiac allograft loss and a leading cause of death beyond the 1st post-transplant year. The influence of ISDs on the development and progression of CAV is complex. In spite ...

journal_title：Current vascular pharmacology

authors： Dandel M,Hetzer R

更新日期：2010-09-01 00:00:00

abstract：:In recent years, the development of more effective drugs has provided a better prognosis and an increase in life expectancy for patients at all-stages of cancer. On the other hand, the price for the improving effectiveness of therapies against malignant tumors is the development of severe and potentially life-threaten...

journal_title：Current vascular pharmacology

authors： Perrino C,Schiattarella GG,Magliulo F,Ilardi F,Carotenuto G,Gargiulo G,Serino F,Ferrone M,Scudiero F,Carbone A,Trimarco B,Esposito G

更新日期：2014-01-01 00:00:00

abstract：:Alterations of fibroblast growth factor 23 (FGF-23) and Klotho levels are considered to be the earliest biochemical abnormality of chronic kidney disease - mineral and bone disease (CKDMBD) syndrome. Moreover, emerging data suggests that the dysregulated FGF-23 and Klotho axis has many effects on the cardiovascular (C...

journal_title：Current vascular pharmacology

authors： Memmos E,Papagianni A

更新日期：2021-01-01 00:00:00

abstract：:The saphenous vein is the most commonly used conduit in patients undergoing coronary artery bypass surgery. However, a high proportion of vein grafts occlude within the first year and over 50% patients require further grafting within 10 years. Using conventional harvesting techniques the saphenous vein is damaged due ...

journal_title：Current vascular pharmacology

authors： Dashwood MR,Loesch A

更新日期：2009-01-01 00:00:00

abstract：:Epidemiological evidence supports a reduced prevalence of Thoracic Aortic Aneurysm (TAA) and Abdominal Aortic Aneurysm (AAA) in patients with Diabetes (DM). The mechanisms underlying this negative association are unknown. Some studies support that hyperglycemia has effects on the Extracellular Matrix (ECM), resulting ...

journal_title：Current vascular pharmacology

authors： Krizhanovskii C,Franco-Cereceda A

更新日期：2019-01-01 00:00:00

abstract：:In end-stage renal disease patients, the leading causes of mortality are of cardiovascular (CV) origin. The underlying mechanisms are complex, given that sudden heart failure is more common than acute myocardial infarction. A contributing role of oxidative stress is postulated, which is increased even at early stages ...

journal_title：Current vascular pharmacology

authors： Roumeliotis S,Roumeliotis A,Gorny X,Mertens PR

更新日期：2021-01-01 00:00:00

abstract：:Chronic kidney disease (CKD) is associated with high cardiovascular morbidity and mortality. The available data suggest that efforts to reduce mortality in the CKD population should be focused on treatment and prevention of, among others, coronary artery disease and congestive heart failure. Accelerated atherosclerosi...

journal_title：Current vascular pharmacology

authors： Franczyk-Skóra B,Gluba A,Banach M,Rozentryt P,Poloński L,Rysz J

更新日期：2013-09-01 00:00:00

abstract：BACKGROUND:The association between Paget's disease of bone (PDB) and increased cardiovascular (CV) risk has been suggested, but the literature is conflicting. OBJECTIVE:Our study aimed to evaluate two markers of CV risk [common carotid artery intima-media thickness (cIMT) and the aortic pulse wave velocity (PWV)] in p...

journal_title：Current vascular pharmacology

authors： Gaudio A,Zanoli L,Xourafa A,Rapisarda R,Catalano A,Signorelli SS,Castellino P

更新日期：2020-06-09 00:00:00

abstract：:The "pleiotropic" effects of statins have been the centre of a considerable research activity. Among the numerous experimental and clinical studies of this field, some focused on the effects of statins on blood pressure (BP), while others reported data on BP together with other parameters. Some of the animal or human ...

journal_title：Current vascular pharmacology

authors： Sarafidis PA,Kanaki AI,Lasaridis AN

更新日期：2007-04-01 00:00:00

abstract：:Autoregulation is a vital homeostatic mechanism that helps maintain constant delivery of oxygen to organs despite fluctuations in arteriolar pressure. Autoregulation of blood flow to elevations in pressure is largely mediated by the myogenic response of small arteries and arterioles which constrict in response to elev...

journal_title：Current vascular pharmacology

authors： Roman RJ,Van Dokkum RP

更新日期：2014-01-01 00:00:00

abstract：:Visfatin is highly expressed in adipose tissue (mainly by the stromal cells), but it is also ubiquitously present in most tissues. Visfatin, which plays a role in nicotinamide adenine dinucleotide (NAD) biosynthesis, has been implicated in inflammatory states. Controversial results exist about the expression, circulat...

journal_title：Current vascular pharmacology

authors： Filippatos TD,Randeva HS,Derdemezis CS,Elisaf MS,Mikhailidis DP

更新日期：2010-01-01 00:00:00

abstract：:Several lines of evidence suggest a detrimental effect of aldosterone excess on the development of metabolic alterations. Glucose metabolism derangements due to aldosterone action are frequently observed not only in patients with primary aldosteronism but also in patients with obesity. A contribution to the hyperaldos...

journal_title：Current vascular pharmacology

authors： Ronconi V,Turchi F,Appolloni G,di Tizio V,Boscaro M,Giacchetti G

更新日期：2012-03-01 00:00:00

abstract：:Revascularization procedures used for the treatment of cardiovascular disease can be associated with restenosis, although drug-coated stents have greatly reduced this complication. Both type 2 diabetes (T2DM) and metabolic syndrome (MetS) are associated with a high risk for atherosclerosis and restenosis. Insulin resi...

journal_title：Current vascular pharmacology

authors： Breen DM,Giacca A

更新日期：2011-05-01 00:00:00

abstract：:Gestational diabetes mellitus (GDM) is a syndrome compromising the health of the mother and the fetus. Endothelial damage and reduced metabolism of the vasodilator adenosine occur and fetal hyperinsulinemia associated with deficient insulin response and a metabolic rather than mitogenic phenotype is characteristic of ...

journal_title：Current vascular pharmacology

authors： Guzmán-Gutiérrez E,Abarzúa F,Belmar C,Nien JK,Ramírez MA,Arroyo P,Salomón C,Westermeier F,Puebla C,Leiva A,Casanello P,Sobrevia L

更新日期：2011-11-01 00:00:00